Price: quote on request. Your total cost is quoted in writing per case.
We give you a written timeline estimate for your case before you commit.
Ask about treatment

Idiopathic pulmonary fibrosis (IPF): US-approved treatments and how families in the Gulf can access them

A plain guide for families in the Gulf, checked against US FDA labels, US National Institutes of Health information, Gulf drug registers and published research on 17 October 2026.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Idiopathic pulmonary fibrosis: the short answer

The US FDA has approved three medicines covered on this page for idiopathic pulmonary fibrosis, each for a specific group of patients: Ofev, Esbriet and Jascayd. On 17 October 2026, three of them were on the Saudi or Abu Dhabi register, so ask your hospital about local supply first. Where a medicine is not registered, the treating hospital can ask the national regulator to import it for one named patient. Reserve Meds is a digital health company that helps with that process. We do not diagnose or prescribe.

  • US FDA-approved medicines on this page: Ofev, Esbriet and Jascayd.
  • Gulf registers (checked 17 October 2026): see each medicine below.
  • Legal route: local supply where listed; otherwise a named-patient import request filed by the treating hospital.
  • Price: Quote on request.

What is idiopathic pulmonary fibrosis?

Idiopathic pulmonary fibrosis (IPF) is a serious, chronic lung disease in which the tissue around the air sacs becomes thick and stiff for unknown reasons. Over time this causes permanent scarring (fibrosis) that makes it harder and harder to breathe.[1, 2]

The most common symptoms are shortness of breath and a persistent dry cough. Many people also lose appetite and weight, and some develop clubbing of the fingers. IPF usually affects people between ages 50 and 70, and the risk is higher in people who smoke or have a family history.[2, 1]

IPF has an estimated prevalence of 13 to 20 per 100,000 people worldwide. Antifibrotic medicines are approved in the US to treat it.[2, 3, 4]

Idiopathic pulmonary fibrosis in the Gulf

Saudi studies include real-life data on nintedanib and pirfenidone for IPF at King Abdulaziz Medical City, Riyadh (2023), a study of clinical characteristics and outcomes of IPF (2020), and a single-center study of interstitial lung diseases in Saudi Arabia (2013).[5, 6, 7]

We checked every medicine on this page against the full SFDA drugs list and the Abu Dhabi Department of Health drug code list on 17 October 2026. 2 of 3 were listed in Saudi Arabia and 3 of 3 in Abu Dhabi. The result for each medicine is shown below. A listing does not mean every hospital stocks the medicine, and federal UAE, Kuwait, Qatar, Bahrain and Oman registers were not checked.[8, 9]

US FDA-approved medicines for idiopathic pulmonary fibrosis

Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.

  • Ofev (nintedanib)
    US FDA-approved for IPF in adults, and other chronic fibrosing interstitial lung diseases with a progressive phenotype. It is a capsule.[3]
    Current US label version: 20 November 2025. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[8, 9]
    Country access guides: Saudi Arabia, UAE, Egypt, India, Pakistan
  • Esbriet (pirfenidone)
    US FDA-approved for idiopathic pulmonary fibrosis. It is pirfenidone, taken by mouth.[4]
    Current US label version: 5 December 2025. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[8, 9]
    Country access guides: Saudi Arabia, UAE, Egypt, India, Pakistan
  • Jascayd (nerandomilast)
    US FDA-approved for IPF in adults, and progressive pulmonary fibrosis. It is a tablet.[10]
    Current US label version: 14 August 2026. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[8, 9]
    Country access guides: Saudi Arabia, UAE, Qatar, Egypt, Jordan, India

How families in the Gulf can access treatment

If the medicine is listed in your country. Ask your specialist and the hospital about local supply first. A listing does not mean every hospital stocks the medicine, but it is usually the fastest route, and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital confirms.[11, 12] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital.

Who does what

  • Your treating specialist decides whether a medicine is right for the patient and writes the medical letter.
  • The hospital checks local supply, files any import request, and gives the treatment safely.
  • The national regulator decides whether to approve the import of a medicine that is not registered.
  • The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
  • Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

  • A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
  • Reports that confirm the diagnosis, such as genetic, pathology, imaging or laboratory results, translated into English where needed
  • Recent clinic notes and a list of current medicines
  • For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
  • Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate for your case before you commit. The regulator, the hospital or treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for idiopathic pulmonary fibrosis

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Include the country code, for example +966 or +971.
Message us on WhatsApp

No account needed. We reply within one business day. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

Frequently asked questions

Is there an FDA-approved treatment for idiopathic pulmonary fibrosis?

Yes. The medicines on this page have US FDA approval for specific groups of patients: Ofev, Esbriet and Jascayd. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.

Is Ofev available in Saudi Arabia or the UAE?

We checked on 17 October 2026. Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (Department of Health drug code list): listed. A listing in Abu Dhabi does not show federal UAE status, which we could not verify. Your hospital confirms current supply.

How can a family in the Gulf get Ofev?

Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Does Reserve Meds diagnose or prescribe?

No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.

Are IPF medicines available in Saudi Arabia?

Ofev and Esbriet were found in the Saudi and Abu Dhabi lists we checked, and a Saudi hospital has published real-life data on both. Ask your lung specialist about local supply first.

Sources for the condition-specific answers: [8, 9, 5]

Sources

Accessed and checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital confirms the current position before anything is filed.

  1. National Heart, Lung, and Blood Institute (NHLBI): Pulmonary Fibrosis
  2. MedlinePlus Genetics (US National Library of Medicine): Idiopathic pulmonary fibrosis
  3. DailyMed: OFEV (nintedanib) US prescribing information, label version 20 November 2025
  4. DailyMed: ESBRIET (pirfenidone) US prescribing information, label version 5 December 2025
  5. Khan MA, et al. Nintedanib and pirfenidone for idiopathic pulmonary fibrosis in King Abdulaziz Medical City, Riyadh: Real-life data. Ann Thorac Med. 2023 (PubMed 36968327)
  6. Alhamad EH, et al. Clinical characteristics, comorbidities, and outcomes in patients with idiopathic pulmonary fibrosis. Ann Thorac Med. 2020 (PubMed 33381235)
  7. Alhamad EH, et al. Interstitial lung diseases in Saudi Arabia: A single-center study. Ann Thorac Med. 2013 (PubMed 23440334)
  8. SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
  9. Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
  10. DailyMed: JASCAYD (nerandomilast) US prescribing information, label version 14 August 2026
  11. SFDA: Special Access Program (SAP) guidance, version 1.0
  12. NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products

Related

This page is general health information, not medical advice. It does not replace a consultation with your doctor.

WhatsApp